AI Overview

Under Trump's tax framework, five top pharmaceutical corporations alone stand to reap an estimated $42.7 billion to $46.8 billion in tax breaks via a proposed 12% "tax holiday" on offshore profits.

Offshore Profit Shifting: 2017 Tax Cuts and Jobs Act (TCJA) set a low 10.5% minimum tax rate on foreign earnings via the Global Intangible Low-Taxed Income (GILTI) system. This cut the tax rate on shifted income in half, allowing companies like Pfizer, Johnson & Johnson, and AbbVie to book the vast majority of their profits abroad while selling primarily to U.S. patients.

Effective Tax Rates: Thanks to these structural loopholes, massive pharma corporations pay almost nothing in U.S. federal taxes. For instance, Pfizer, Johnson & Johnson, and AbbVie effectively paid $0 in federal income taxes on billions in profits in recent years.

The "Carrot and Stick" Reshoring StrategyThe Trump administration has combined tax incentives with aggressive trade policies to force companies to bring manufacturing back to the U.S.:

The Tariffs (The "Stick"): The White House instituted a 100% tariff on patented pharmaceuticals and ingredients imported into the U.S..

Tariff Relief (The "Carrot"): Drug companies that submit approved onshoring and production plans to the Department of Commerce are granted a reduced tariff rate of 20%.

Repatriation Windfalls: Proposals tied to the legislative push would allow drugmakers to hoard intellectual property (IP) abroad and bring accumulated cash back to the U.S. at a steep discount, saving Pfizer alone an estimated $24.4 billion to $26.7 billion.
--------------------